# AccuraGen

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/accuragen

- Industry: Healthcare
- Headquarters: Menlo Park, US
- Website: www.accuragen.com
- Total disclosed funding: $40M
- Latest round: Series B (Jun 1, 2016)
- Investors on record: 5

## About

AccuraGen is a biotechnology firm specializing in innovative liquid biopsy solutions for non-invasive cancer diagnostics, utilizing advanced DNA and RNA sequencing technologies to provide critical insights into personalized treatment options.Founded in 2013 in Menlo Park, US, AccuraGen develops liquid biopsy technologies aimed at improving cancer diagnostics. The company has raised a total of USD 40 mn, including USD 40 mn in its Series B funding round on June 1, 2016, with notable investors such as BDT Capital Partners and Temasek Holdings. The company is led by CEO Kang Ying, who is one of the co-founders, and has been involved in founding other ventures in the sector.AccuraGen, Inc. specializes in innovative liquid biopsy solutions that facilitate non-invasive cancer diagnostics through advanced DNA and RNA sequencing. The company's core technology employs rolling-circle amplification for accurate genetic analysis, critical for personalized treatment plans and monitoring minimal residual disease (MRD). Their products serve healthcare providers, research institutions, and clinical laboratories primarily in North America and Europe, supporting targeted cancer therapy selection, real-time disease monitoring, and population-level screening.AccuraGen generates revenue through partnerships and collaborations with medical institutions and research organizations, integrating its liquid biopsy technology into clinical settings. The revenue model includes service agreements and sales of diagnostic assays, sold primarily on a B2B basis to healthcare providers for patient testing. The scalable design of their flagship products allows healthcare providers to conduct regular monitoring and testing in line with personalized medicine trends, establishing a sustainable revenue framework in oncology.AccuraGen aims to enhance its market presence by launching new liquid biopsy products aimed at improving diagnostic accuracy and patient outcomes. The company plans to expand into international markets, particularly in Asia by 2025, leveraging its recent Series B funding of USD 40 mn raised in June 2016 to fuel these initiatives. This funding will support product development and market entry strategies as AccuraGen seeks to establish a stronger foothold in emerging regions.

## Funding rounds

- Series B, Jun 1, 2016, $40M — Temasek Holdings, BDT Capital Partners, Decheng Capital, Junson Capital, Stanford-StartX Fund

## Investors

- Temasek Holdings — Series B
- BDT Capital Partners (https://capitalatlas.ai/funds/bdt-capital-partners) — Series B
- Decheng Capital (https://capitalatlas.ai/funds/decheng-capital) — Series B
- Junson Capital — Series B
- Stanford-StartX Fund — Series B